FDG PET/MR for the Assessment of Lymph Node Involvement in Lymphoma. Initial Results and Role of Diffusion-Weighted MR

Academic Radiology

Volumn 21, Issue 10, 2014, Pages 1314-1319

  Platzek, Ivan ^a   Beuthien Baumann, Bettina ^a   Ordemann, Rainer ^a   Maus, Jens ^b   Schramm, Georg ^b   Kitzler, Hagen H ^a   Laniado, Michael ^a   Kotzerke, Jörg ^a   van den Hoff, Jörg ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

Author keywords

Lymphoma; PET MR; Sensitivity; Specificity; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BURKITT LYMPHOMA; CANCER STAGING; CLINICAL ARTICLE; CUTANEOUS T CELL LYMPHOMA; DIAGNOSTIC TEST ACCURACY STUDY; FEASIBILITY STUDY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPH NODE; LYMPHOMA; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PET-MRI SCANNER; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STANDARD; YOUNG ADULT; DIAGNOSTIC USE; DIFFUSION WEIGHTED IMAGING; MULTIMODAL IMAGING; PATHOLOGY; PILOT STUDY; PROCEDURES; REPRODUCIBILITY;

ADOLESCENT; ADULT; AGED; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHOMA; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM STAGING; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84908255108     PISSN: 10766332     EISSN: 18784046     Source Type: Journal    
DOI: 10.1016/j.acra.2014.05.019     Document Type: Article

References (20)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 2007, 57(1):43-66.
2. Sant M., Allemani C., Tereanu C., et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010, 116(19):3724-3734.
3. Weiler-Sagie M., Bushelev O., Epelbaum R., et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010, 51(1):25-30.
4. Hicks R.J., Mac Manus M.P., Seymour J.F. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 2005, 35(3):165-175.
5. Reske S.N. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 2003, 30(Suppl 1):S89-S96.
6. Juweid M.E., Stroobants S., Hoekstra O.S., et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. JClin Oncol 2007, 25(5):571-578.
7. Schwenzer N.F., Schraml C., Muller M., et al. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging-pilot study. Radiology 2012, 264(2):551-558.
8. Platzek I., Beuthien-Baumann B., Langner J., et al. PET/MR for therapy response evaluation in malignant lymphoma: initial experience. MAGMA 2013, 26(1):49-55.
9. Schramm G., Langner J., Hofheinz F., et al. Quantitative accuracy of attenuation correction in the Philips Ingenuity TF whole-body PET/MR system: a direct comparison with transmission-based attenuation correction. MAGMA 2012.
10. Torigian D.A., Lopez R.F., Alapati S., et al. Feasibility and performance of novel software to quantify metabolically active volumes and 3D partial volume corrected SUV and metabolic volumetric products of spinal bone marrow metastases on 18F-FDG-PET/CT. Hell J Nucl Med 2011, 14(1):8-14.
11. Boellaard R., O'Doherty M.J., Weber W.A., et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010, 37(1):181-200.
12. Shankar L.K., Hoffman J.M., Bacharach S., et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006, 47(6):1059-1066.
13. Eich H.T., Staar S., Gossmann A., et al. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 2004, 58(4):1121-1127.
14. Zaidi H., Ojha N., Morich M., et al. Design and performance evaluation of a whole-body ingenuity TF PET-MRI system. Phys Med Biol 2011, 56(10):3091-3106.
15. Delso G., Furst S., Jakoby B., et al. Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med 2011, 52(12):1914-1922.
16. Freudenberg L.S., Antoch G., Schutt P., et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004, 31(3):325-329.
17. Hutchings M., Loft A., Hansen M., et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 2006, 91(4):482-489.
18. Cerci J.J., Trindade E., Buccheri V., et al. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions. Clin Lymphoma Myeloma Leuk 2011, 11(4):314-320.
19. Silva A.C., Lawder H.J., Hara A., et al. Innovations in CT dose reduction strategy: application of the adaptive statistical iterative reconstruction algorithm. AJR Am J Roentgenol 2010, 194(1):191-199.
20. Leide-Svegborn S. Radiation exposure of patients and personnel from a PET/CT procedure with 18F-FDG. Radiat Prot Dosimetry 2010, 139(1-3):208-213.